AFAliance Romain Fokoua

Aliance Romain Fokoua

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aliance Romain Fokoua has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Benneth Ben-Azu

    DELSU Joint Canada‐Israel Neuroscience and Biopsychiatry Laboratory, Department of Pharmacology, Faculty of Allied Health Sciences, College of Health Sciences Delta State University Abraka Delta State Nigeria

    4 shared publications
  • Télesphore Benoît Nguelefack

    Research Unit of Animal Physiology and Phytopharmacology, Faculty of Sciences, University of Dschang, Dschang, Cameroon

    4 shared publications
  • Jean Rodolphe Chouna

    Department of Chemistry, Faculty of Science, University of Dschang, P.O. Box 67, Dschang, Cameroon

    2 shared publications
  • Olusegun G. Adebayo

    DELSU Joint Canada-Israel Neuroscience and Biopsychiatry Laboratory, Department of Pharmacology, Faculty of Basic Medical Sciences, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria; Neurophysiology Unit, Department of Physiology, Faculty of Basic Medical Sciences, University of Ibadan, Ibadan, Oyo State, Nigeria

    2 shared publications
  • Pepin Alango Nkeng-Efouet

    Fondation Alango-Reference Hospital of African medicine, Dschang, Cameroon

    2 shared publications
  • Sorelle Ngassam Mbankou

    Research Unit of Animal Physiology and Phytopharmacology, Faculty of Sciences, University of Dschang, Dschang, Cameroon

    2 shared publications

Latest Publications

  • Open Access

    Naloxone-precipitated morphine withdrawal syndrome: a neurobiochemical brain network investigation and model characterization in mice

    by Brice Emmanuel Tutchamo, Aliance Fokoua, Francis Désiré Bomba Tatsinkou, Sorelle Mbankou, Junior Tiokeng Asahafou, Ludovine Claire Tindo, Judith Manialeu Pouadjeu, Bibiane Aimée Wandji, Elvine Pami Nguelefack-Mbuyo, Télesphore Benoît Benoit Nguelefack

    Efforts to resolve the opioid crisis are hindered by withdrawal syndrome, whose neurochemical basis across brain regions remains unclear. This study attempted to find the naloxone dose that best induce the behavioral and neurochemical alterations, and the association between the two. Mice were treated with morphine (48 mg/kg/day) for ten days, during which tactile allodynia, grip test, and locomotor activity were monitored. On day 10, morphine treated groups received naloxone intraperitoneally at 3 or 5 mg/kg. Then, withdrawal behavior (jump, grooming, and wed dog shake) was observed. On day 11, animals underwent hot plate and acetone tests. Thereafter, serum, Prefrontal cortex (PFC), striatum, hippocampus, cerebellum, the rest of the brain (RB), and spinal cord (SC) were collected to assay IL-1β, TNF-α, dopamine, noradrenaline and acetylcholine esterase (AChE) activity. Principal component analysis was used to identify relationship between biochemical and behavior. Morphine administration decreased body mass and tactile pain threshold. Naloxone reduced the time on grid and animal mobility. It increased jumps and wet dog shake. A relationship was observed between AChE in the RB and SC, and the locomotor activity. Withdrawal global score was related to norepinephrine level in the PFC, cerebellum and RB. Pain-like behaviour was related to dopamine level in the striatum and the SC. Naloxone 3 mg/kg was the more effective dose to induce withdrawal syndrome. The behavioural signs of dependence and withdrawal syndrome are mediated through a complex intermingled biochemical circuitry that differentially implicate dopamine, norepinephrine and cholinergic tone from SC and distinct brain regions.

  • Open Access

    Towards Mechanism‐Informed Treatments for Mental Health

    by Iker Bengoetxea de Tena, Farhanah Nabilah Sallie, Arvie Rodriguez Abiero, Beatrice Rizzi, Leandro Gabriel Champarini, Elisa Corti, Gianluca Masella, Ariel L. Dunn, Luisa Bandeira Binder, Tyler J. Wenzel, et al.

    Neuropsychiatric disorders represent a significant global health burden. Despite decades of research, current treatments typically provide only symptomatic relief, rather than addressing the underlying mechanisms of these conditions. Historically, research focused on the dopaminergic and serotonergic systems, which are deeply involved in the pathophysiology of many mental health disorders, including depression, schizophrenia, anxiety, autism spectrum disorder (ASD), and different substance use disorders, including alcohol use disorder (AUD). However, therapies targeting these systems have limitations, often only producing partial symptom relief plus compliance‐limiting side effects. This highlights the need for improved treatments that may emerge from a broader understanding of the neurobiological bases of these conditions, especially neurochemical systems beyond dopamine and serotonin. Additional monoamines (e.g., histamine, acetylcholine, norepinephrine), neurolipid systems (e.g., endocannabinoids), and diverse signaling molecules such as neuropeptides, trace amines, and cytokines are increasingly recognized as key players in the dysfunction of neural circuits. In this review, which originated from the International Society for Neurochemistry (ISN)/Journal of Neurochemistry 5th Flagship School in October 2024 held in Naxos, Greece, we describe the importance of these neuromodulatory systems in the pathophysiology of select neuropsychiatric disorders, discuss their potential as targets for therapeutic intervention, exploring how they may offer more effective, mechanism‐based treatments. We also highlight recent clinical trials, underscoring the progress in advancing towards clinical application, as well as sex‐specific neurobiological differences, a historically overlooked, yet fundamental determinant of the pathophysiology of neuropsychiatric disorders. We propose that expanding our focus beyond traditional monoamines offers a promising avenue for the development of new, disease‐modifying treatments that can more effectively address the underlying causes of neuropsychiatric disorders. By targeting these pathways, we believe it may be possible to develop therapies that restore balance to dysregulated brain circuits and improve long‐term outcomes for patients. image

  • Open Access

    Aqueous and Ethanol Extracts of Acacia sieberiana (Fabaceae) Stem Bark Reverse the Pain–Depression Dyad in Mice Through Modulation of Catecholamines, Proinflammatory Cytokines, and Oxidative Stress

    by Sorelle Ngassam Mbankou, Aliance Romain Fokoua, Cedric Wamba Koho, Roger Hermann Sadie Foguieng, Sahar Mofidi Tabatabaei, Pamela Arielle Nono Nankam, Kevin Joseph Tidgewell, Télesphore Benoît Nguelefack

    Rationale and Objective: The pain–depression dyad is highly prevalent and has reciprocal psychological and behavioral effects, leading to poor quality of life, increased disability, and challenging therapeutic outcomes. In an attempt to find better substances that can target pain–depression comorbidity, we examined the effect of aqueous (AE) and ethanol (EE) extracts from Acacia sieberiana ( A. sieberiana ) stem bark on reserpinized mice (female and male Swiss albino mice aged 2‐3 months). Methods: The dyad was induced with 3 injections (Days 1–3) of reserpine (1 mg/kg/day, s.c .). Then, animals were treated (Days 4–8) with plant extracts (25, 50 and 100 mg/kg/day, p.o .) or L‐tryptophane (100 mg/kg/day, i.p .). Pain‐like (tactile and cold allodynia) and depression‐like (pole, tail suspension, and force swimming tests) behavioral parameters were evaluated on Days 4 and 8. On Day 9, animals were sacrificed for the quantification of acetylcholinesterase activity, oxidative stress parameters, total catecholamines, dopamine, serotonin, IL‐1β, and TNF‐α levels in the brain or spinal cord. IL‐1β and TNF‐α were also assayed in the serum. The acute toxicity and phytochemical analysis of EE were conducted. Results: Reserpine‐induced tactile and cold allodynia, depression‐like behavior, increased serum IL‐1β and TNF‐α, brain acetylcholinesterase activity, and decreased catecholamine concentration were all reversed by AE and EE. Plant extracts significantly increased dopamine levels and reduced oxidative stress in the brain and/or spinal cord. No significant effect was observed on brain serotonin and TNF‐α. EE elicited the best pharmacological activity and was nontoxic. LC–MS/MS molecular networking phytochemical analysis identified 5 compounds with high certainty including piperine, aurantiamide acetate, and asperphenamate. Conclusion: AE and EE are effective against pain and depression. Their pharmacological activities might be related to the modulation of inflammation, oxidative stress and catecholamine, and the presence of bioactive natural products.


  • Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action

    by Benneth Ben-Azu, Aliance R. Fokoua, Olajide S. Annafi, Olusegun G. Adebayo, Elisabetta C. del Re, Nneka Okuchukwu, Gbemileke J. Aregbesola, Akpor-Esiri C. Ejenavi, David M. Isiwele, Arausi J. Efezino, et al.


  • Alcohol exacerbates post-traumatic stress psychiatric behavior and its neuropathological sequalae in experimental mice: preventive effects of morin

    by Benneth Ben-Azu, Pere-Ebi Y. Toloyai, Adaeze Adebesin, Vivian O. Ojiokor, Olusegun G. Adebayo, Aliance Romain Fokoua, Goodes E. Moke, Elo J. Ejukolemu, Ife-Oluwa O. Akpojevughe, Abdulkareem M. Abdulkadir, et al.


  • Open Access

    Containment of neuroimmune challenge by diosgenin confers amelioration of neurochemical and neurotrophic dysfunctions in ketamine-induced schizophrenia in mice

    by Benneth Ben-Azu, Olusegun G. Adebayo, Aliance R. Fokoua, Jackson E. Onuelu, Jerome N. Asiwe, Emuesiri G. Moke, Itivere A. Omogbiya, Oghenemarho L. Okpara, Jennifer E. Okoro, Omadevuaye M. Oghenevwerutevwe, et al.


  • The antioxidant and neuroprotective effects of the Psychotria camptopus Verd. Hook. (Rubiaceae) stem bark methanol extract contributes to its antiepileptogenic activity against pentylenetetrazol kindling in male Wistar rats

    by Aliance Romain Fokoua, Abayomi Mayowa Ajayi, Benneth Ben-Azu, Rodolphe Chouna, Oluwabusayo Folarin, James Olopade, Pepin Alango Nkeng-Efouet, Adegbuyi Oladele Aderibigbe, Solomon Umukoro, Télesphore Benoît Nguelefack

    A substantial number of epileptic patients are resistant to the current medication thus necessitating the search for alternative therapies for intractable forms of the disease. Previous studies demonstrated the acute anticonvulsant properties of the methanol extract of the stem bark of Psychotria camptopus (MEPC) in rats. This study investigated the effects of MEPC on pentylenetetrazole-kindled Wistar rats. Kindling was induced by intraperitoneal injection of pentylenetetrazole (37.5 mg/kg) on every alternate day, 1 h after each daily oral pretreatment of rats (8 ≤ n ≤ 10) with MEPC (40, 80 and 120 mg/kg), vehicle or diazepam (3 mg/kg) for 43 days. The kindling development was monitored based on seizure episodes and severity. Rats’ brains were collected on day 43 for the determination of oxidative stress parameters. The histomorphological features and neuronal cell viability of the prefrontal cortex (PFC) and hippocampus were also assessed using H&E and Cresyl violet stains. Chronic administration of pentylenetetrazole time-dependently decreased the latency to myoclonic and generalized seizures, and increased seizure scores and the number of kindled rats. MEPC and diazepam significantly increased the latencies to myoclonic jerks and generalized tonic-clonic seizures. These substances also reduced seizure score and the number of rats with PTZ-kindling. MEPC improved glutathione status and decreased lipid peroxidation in the brains of kindled rats. MEPC also exhibited neuroprotection against pentylenetetrazole-induced hippocampal and PFC neuronal damages. These results suggest that P. camptopus has antiepileptogenic activity, which might be related to the augmentation of antioxidant and neuroprotective defense mechanisms, and further confirm its usefulness in the management of epilepsy.


  • Anticonvulsant effects of the aqueous and methanol extracts from the stem bark of Psychotria camptopus Verdc. (Rubiacaea) in rats

    by Aliance Romain Fokoua, Magloire K. Ndjenda, Adeline Kaptué Wuyt, Francis Desire Tatsinkou Bomba, Appolinaire Kene Dongmo, Rodolphe Chouna, Pepin Alango Nkeng-Efouet, Télesphore Benoît Nguelefack